- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | AROA BIOSURGERY LIMITED: Notice of AGM Date and Director Nomination Closing Date | - | ASX | ||
| 27.05. | AROA BIOSURGERY LIMITED: Change in substantial holding | - | ASX | ||
| 26.05. | Biocurious: Aroa brings a touch of 'magic' to the US$3 billion woundcare sector | 1 | Stockhead | ||
| 26.05. | AROA BIOSURGERY LIMITED: FY26 Full Year Results Presentation - Correction | - | ASX | ||
| AROA BIOSURGERY Aktie jetzt für 0€ handeln | |||||
| 26.05. | Aroa Biosurgery Sets Ambitious FY27 Targets after Exceeding FY26 Guidance | 2 | smallcaps.com.au | ||
| 25.05. | AROA BIOSURGERY LIMITED: FY26 Full Year Results Presentation | - | ASX | ||
| 25.05. | AROA BIOSURGERY LIMITED: FY26 Appendix 4E and Full Year Results | - | ASX | ||
| 18.05. | AROA BIOSURGERY LIMITED: Notification of Full Year Results Webinar | - | ASX | ||
| 30.04. | Health Check: Investors say "not baa-d" as Aroa smashes earnings expectations out of the paddock | 3 | Stockhead | ||
| 29.04. | AROA BIOSURGERY LIMITED: ARX FY26 Preliminary Results | - | ASX | ||
| 10.04. | AROA BIOSURGERY LIMITED: Application for quotation of securities - ARX | - | ASX | ||
| 09.04. | AROA BIOSURGERY LIMITED: Notification of cessation of securities - ARX | - | ASX | ||
| 30.03. | Aroa Biosurgery's Symphony Shows Positive Preliminary Results For Diabetic Foot Ulcers | 2 | RTTNews | ||
| 30.03. | AROA Biosurgery Completes Randomised Controlled Trial for Symphony; Preliminary Read-Out indicates Primary Endpoint Met | 345 | PR Newswire | AUCKLAND, New Zealand, March 29, 2026 /PRNewswire/ -- Aroa Biosurgery Limited today announced completion of its randomised controlled trial (RCT) evaluating Symphony... ► Artikel lesen | |
| 29.03. | AROA BIOSURGERY LIMITED: Symphony Randomised Control Trial Complete | - | ASX | ||
| 24.03. | AROA BIOSURGERY LIMITED: Release of Shares from Voluntary Escrow | 1 | ASX | ||
| 10.03. | Vital Signs Podcast: Inside Aroa's MASTRR clinical registry | 1 | Stockhead | ||
| 03.02. | AROA BIOSURGERY LIMITED: Application for quotation of securities - ARX | - | ASX | ||
| 03.02. | AROA BIOSURGERY LIMITED: Eligible NZ Employees Issued with ARX Shares | - | ASX | ||
| 02.02. | AROA BIOSURGERY LIMITED: AROA Business Update Presentation | - | ASX |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,85 | -0,13 % | BioNTech-Aktie: Ist das Unternehmen noch zu retten? | Die Geschichte von BioNTech ist eine der größten Erfolgsgeschichten der deutschen Wirtschaft. Aus einem Mainzer Forschungsunternehmen wurde innerhalb weniger Jahre ein globaler Pharmakonzern, dessen... ► Artikel lesen | |
| EVOTEC | 4,906 | +1,41 % | Blockbuster, Gold und Insiderverkäufe - Bayer AG, Evotec, North Arrow Minerals | Der erneute israelische Angriff im Libanon blockiert die eh schon unsicheren US-Iran-Gespräche massiv. Da Teheran die Hisbollah im Libanon unterstützt und den Frieden mit den USA an einen Frieden zwischen... ► Artikel lesen | |
| MODERNA | 57,96 | -1,91 % | Moderna-Aktie +12%: Und plötzlich sind alle euphorisch | Mit einem Kurssprung von +12% setzt sich die Moderna-Aktie am Freitag an die Spitze des Nasdaq 100 und steigt auf den höchsten Stand seit September 2024. Was beflügelt die Aktie des Biotech-Unternehmens... ► Artikel lesen | |
| NOVAVAX | 7,750 | -0,77 % | Novavax faces renewed attack by Shah Capital after AGM | ||
| HEIDELBERG PHARMA | 2,650 | +2,32 % | EQS-News: Heidelberg Pharma AG: Heidelberg Pharma berichtet über die Ergebnisse der ordentlichen Hauptversammlung 2026 | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Hauptversammlung
Heidelberg Pharma berichtet über die Ergebnisse der ordentlichen Hauptversammlung 2026
23.06.2026 / 15:39... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,969 | +0,68 % | INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen | |
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| TREVENA | 4,000 | +1.983 % | TREVENA INC - 8-K, Current Report | ||
| BIOMARIN PHARMACEUTICAL | 49,300 | -2,03 % | Stifel reiterates Hold on BioMarin stock, keeps $68 price target | ||
| VAXART | 0,380 | 0,00 % | Vaxart, Inc. - 8-K, Current Report | ||
| IBIO | 1,443 | -1,30 % | iBio, Inc.: iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity | IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition First-in-human study of IBIO-600 to evaluate safety,... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 4,000 | +0,25 % | Arbutus Biopharma Corporation: Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities... ► Artikel lesen | |
| LAKEFRONT BIOTHERAPEUTICS | 25,140 | -2,18 % | Lakefront Biotherapeutics NV - 6-K, Report of foreign issuer | ||
| CELLECTAR BIOSCIENCES | 2,520 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase... ► Artikel lesen | |
| CYTODYN | 0,210 | 0,00 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease | Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11... ► Artikel lesen |
AROA BIOSURGERY LIMITED gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AROA BIOSURGERY LIMITED finden Sie auf Wallstreet Online.